World Library  
Flag as Inappropriate
Email this Article

Metiamide

Article Id: WHEBN0002967747
Reproduction Date:

Title: Metiamide  
Author: World Heritage Encyclopedia
Language: English
Subject: Burimamide, List of MeSH codes (D02), H2 receptor antagonists, Imidazolines, Thioethers
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Metiamide

Metiamide
Metiamide
Names
IUPAC name
N-methyl-N'-(2-{[(4-methyl-1H-imidazol-5-yl)methyl]thio}ethyl)thiourea
Identifiers
ChEMBL  Y
ChemSpider  Y
DrugBank  Y
Jmol-3D images Image
PubChem
UNII  Y
Properties
C9H16N4S2
Molar mass 244.38 g mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
 Y  (: Y/N?)

Metiamide is a histamine H2-receptor antagonist developed from another H2 antagonist, burimamide.[1] It was an intermediate compound in the development of the successful anti-ulcer drug cimetidine (Tagamet).[2]

Contents

  • Development of metiamide from burimamide 1
  • Modification of metiamide to cimetidine 2
  • Synthesis 3
  • References 4

Development of metiamide from burimamide

After discovering that burimamide is largely inactive at physiological pH, due to the presence of its electron donating side chain, the following steps were undertaken to stabilize burimamide:

  • addition of a sulfide group close to the imidazole ring, giving thiaburimamide
  • addition of methyl group to the 4- position on the imidazole ring to favour the tautomer of thiaburimamide which binds better to the H2-receptor

These changes increased the bioavailability metiamide so that it is 10 times more potent than burimamide in inhibiting histamine-stimulated release of gastric acid.[2] The clinical trials that began in 1973 demonstrated the ability of metiamide to provide symptomatic relief for ulcerous patients by increasing healing rate of peptic ulcers. However, during these trials, an unacceptable number of patients dosed with metiamide developed agranulocytosis (decreased white blood cell count).[2]

Modification of metiamide to cimetidine

It was determined that the thiourea group was the cause of the agranulocytosis. Therefore, replacement of the =S in the thiourea group was suggested:

  • with =O or =NH resulted in a compound with much less activity (20 times less than metiamide)
  • however, the NH form (the guanidine analogue of metiamide) did not show agonistic effects
  • to prevent the guanidine group being protonated at physiological pH, electron-withdrawing groups were added
  • adding a -C≡N or -NO2 group prevented the guanidine group being protonated and did not cause agranulocytosis

The nitro and cyano groups are sufficiently electronegative to reduce the pKa of the neighbouring nitrogens to the same acidity of the thiourea group, hence preserving the activity of the drug in a physiological environment.

Synthesis

Metiamide synthesis:[3][4]

Reacting 2-chloro ethyl acetoacetate (1) with 2 molar equivalents of formamide (2) gives 4-carboethoxy-5-methylimidazole (3). Reduction of imidazole carboxylic ester (3) with sodium in liquid ammonia (à la 'Birch reduction') gives the corresponding 1° carbinol (4) Reaction of that with cysteamine (mercaptoethylamine), as its hydrochloride, leads to intermediate 5. In the strongly acid medium, the amine is completely protonated; this allows the thiol to express its nucleophilicity without competition and the acid also activates the alcoholic function toward displacement. Finally, condensation of the amine with methyl isothiocyanate gives metiamide (6).

References

  1. ^  
  2. ^ a b c -receptor Antagonists"2: Discovery of Histamine H®"Tagamet. National Historic Chemical Landmarks. American Chemical Society. Retrieved June 25, 2012. 
  3. ^ Durant, G. J.; Emmett, J. C.; Ganellin, C. R.; Roe, A. M.; Slater, R. A. (1976). "Potential histamine H2-receptor antagonists. 3. Methylhistamines". Journal of Medicinal Chemistry 19 (7): 923.  
  4. ^ Durant, G. J.; Emmett, J. C.; Ganellin, C. R.; Miles, P. D.; Parsons, M. E.; Prain, H. D.; White, G. R. (1977). "Cyanoguanidine-thiourea equivalence in the development of the histamine H2-receptor antagonist, cimetidine". Journal of Medicinal Chemistry 20 (7): 901.  


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.